Previous close | 1.0600 |
Open | 1.0600 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 79.00 |
Expiry date | 2024-06-28 |
Day's range | 1.0600 - 1.0600 |
Contract range | N/A |
Volume | |
Open interest | N/A |
The European Commission approves AstraZeneca's (AZN) Truqap in combination with Faslodex for ER-positive, HER2-negative advanced or metastatic breast cancer.
The United Kingdom's financial markets are currently poised at a critical juncture, with the FTSE 100's movements closely tied to the upcoming release of May's inflation data and decisions from the Bank of England. Amid these market conditions, identifying undervalued stocks can offer investors potential opportunities for growth in a fluctuating economic environment.
AstraZeneca's (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer fails to meet the dual primary endpoints.